作者
Nicholas CP Cross, Helen E White, Thomas Ernst, Linda Welden, Christian Dietz, Giuseppe Saglio, Francois-Xavier Mahon, Connie C Wong, Dan Zheng, Stephane Wong, Sha-Sha Wang, Susanna Akiki, Francesco Albano, H Andrikovics, J Anwar, G Balatzenko, I Bendit, J Beveridge, Nancy Boeckx, N Cerveira, SM Cheng, D Colomer, S Czurda, F Daraio, S Dulucq, L Eggen, H El Housni, G Gerrard, M Gniot, Barbara Izzo, D Jacquin, JJWM Janssen, S Jeromin, T Jurcek, DW Kim, K Machova-Polakova, J Martinez-Lopez, M McBean, S Mesanovic, G Mitterbauer-Hohendanner, H Mobtaker, MJ Mozziconacci, T Pajič, N Pallisgaard, P Panagiotidis, RD Press, YZ Qin, J Radich, Tomasz Sacha, T Touloumenidou, P Waits, E Wilkinson, R Zadro, Martin C Müller, Andreas Hochhaus, Susan Branford
发表日期
2016/9
期刊
Leukemia
卷号
30
期号
9
页码范围
1844-1852
出版商
Nature Publishing Group
简介
Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1 reference panel was developed (MR 1–MR 4), but access to the material is limited. In this study, we describe the development of the first cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR 4.5 level. The secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories worldwide. Interestingly, we found that> 40% of BCR-ABL1 assays showed signs of inadequate optimization such as poor …
学术搜索中的文章
NCP Cross, HE White, T Ernst, L Welden, C Dietz… - Leukemia, 2016